Crossmark

Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)

Crossref DOI link: https://doi.org/10.1186/s40360-025-00894-3

Published Online: 2025-03-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Hao

Zhu, Chen

Liu, Shuang

Bi, Yingmin

Hu, Jindong

Ju, Mohan
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82002176)

Shanghai Municipal Health Commission (20214Y0392)
License Information

Text and Data Mining valid from 2025-03-11

Version of Record valid from 2025-03-11
More Information

Article History

Received: 17 December 2024

Accepted: 7 March 2025

First Online: 11 March 2025

Declarations

:

: Not applicable.

: The requirement for obtaining individual patient consent was waived as the study did not have an impact on clinical care and all protected health information was de-identified.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below